Tian Xu

Tian Xu is Co-Founder of Double Rainbow. Since 2018, he is Chair Professor of Genetics and Vice-President at Westlake University. Dr. Xu’s work focuses on mechanisms of growth control and new genetic and biotech methods. His studies have not only elucidated fundamental principles of developmental biology, but also revealed pathogenic mechanisms, and contributed to the development of multiple drugs and to cancer and rare disease diagnosis.

Dr. Xu is an AAAS Fellow, and the recipient of the Helen Hay Whitney Postdoctoral Fellowship, the Pew Scholar Award, the Tuberous Sclerosis Alliance Rothberg Courage Award, TSC Achievement Award, Distinguished Scientist and SCBA Service Award, Shanghai Science and Technology Award (1st class), and the Magnolia Silver Award.

He was a postdoctoral fellow at University of California, Berkeley from 1990 to 1993, and an Assistant Professor, Associate Professor (tenured in 2001), and C.N.H. Long Professor of Genetics at Yale University from 1993 to 2018. In addition, he served as Special Advisor to the President of Yale University from 2002 to 2013, and as Vice-Chairman of the Department of Genetics at Yale from 2003 to 2018.

From 1997 to 2018, Dr. Xu served as an Investigator with the Howard Hughes Medical Institute, as well as an Adjunct Professor and Director of the Institute of Developmental Biology, and Director of the International Collaboration and Research Center for Development and Disease at Fudan University.

He received his B.S. degree (1982) from Fudan University and Ph.D. degree (1990) from Yale University. Dr. Xu has served as a scientific advisor for CuraGen, Butterfly Network, Hyperfine Research, Quantum-Si, Yiviva, and Fosun Pharma, and is the inventor of more than 20 international patents.

In addition to Double Rainbow, Dr. Xu is a Co-Founder of LAM Therapeutics (now AI Therapeutics), Drug Farm, and Fosun Lead.